The GLP-1 trend: What the real-world data reveals
GLP-1 Trends: Ozempic and Semaglutide drive a 587% spike in prescriptions Prescriptions for GLP-1...
A better way to measure healthcare costs in closed claims data This is the second post in our four-part taXonomy X blog series (part 1 here), and here we’ll discuss one of the most common pain points in closed claims analytics: costs. Specifically,...
GLP-1 Trends: Ozempic and Semaglutide drive a 587% spike in prescriptions Prescriptions for GLP-1...
Prostate cancer is the most common cancer among men, aside from skin cancer, and is known for being...
FDA's AI guidance is reshaping real-world data standards Artificial Intelligence (AI) is rapidly...
Thank you to everyone who joined us at ISPOR 2025 in Montreal. Whether you stopped by our booth,...
Why data provenance matters for regulatory submissions and clinical trials Regulators increasingly...
This is part three of a three-part series on the essential qualities of claims data for life...
This is part two of a three-part series (read part 1, part 3) on the essential qualities of claims...
This is part one of a three-part series (read part 2, part 3) on the essential qualities of claims...
The problem with Zombie Data—And the critical need for Verified Data In life sciences, where...
Key benefits of real-world lab data for life sciences and pharma Real-world lab results enhance...
A better way to measure healthcare costs in closed claims data This is the second post in our four-part taXonomy X blog series (part 1 here), and here we’ll discuss one of the most common pain points in closed claims analytics: costs. Specifically, w...